Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBM-Regulating Legislation In North Dakota Opposed By FTC

This article was originally published in The Pink Sheet Daily

Executive Summary

A bill before the North Dakota state legislature would limit PBMs’ ability to reduce prescription drug costs, Federal Trade Commission staff says in a letter to a state lawmaker. The legislation would regulate PBMs’ contracts with pharmacies and prohibit certain drug substitutions.

You may also be interested in...



FTC's Comments On PBMs Are Unproductive, State Legislators Say

National Legislative Association on Prescription Drug Prices criticizes the Federal Trade Commission's recent comments on state bills that would mandate greater PBM transparency, claiming FTC ignores evidence of deceptive practices and the need for state regulation.

FTC's Comments On PBMs Are Unproductive, State Legislators Say

National Legislative Association on Prescription Drug Prices criticizes the Federal Trade Commission's recent comments on state bills that would mandate greater PBM transparency, claiming FTC ignores evidence of deceptive practices and the need for state regulation.

California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger

Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel